Navigation Links
Adult stem cell research at UB targets damaged hearts

A specialist in stem cell biology at the University at Buffalo has received a $1.98 million grant from National Institutes of Health to investigate the potential of bone marrow-derived adult stem cells to treat the serious heart malfunction known as hibernating myocardium.

Hibernating myocardium is a condition in which heart cells that have experienced reduced blood flow over an extended period of time due to narrowed coronary arteries adapt to this deprivation by down-regulating metabolism while remaining functionally viable.

Previous work in UB's Center for Cardiovascular Research employing the center's novel swine model of hibernating myocardium has shown that restoring normal blood flow to these "hibernating" regions improves function. However, these results also found that cells in the left ventricle, the heart's main pumping chamber, often do not return to normal, leaving the heart compromised.

The new research is headed by Te-Chung Lee, Ph.D., associate professor of biochemistry in the School of Medicine and Biomedical Sciences and an investigator with the cardiovascular research center.

Lee and colleagues will use the swine model to investigate whether transplanting the model's own bone marrow mesenchymal stem cells (MSC) -- cells that have the capacity to develop into blood vessels, as well as other types of tissues -- into the down-regulated tissue can change the myocardial adaptive responses and improve the function of the hibernating myocardium.

"My colleagues and I already have carried out initial stem-cell transplantation studies with promising results," said Lee. "Additional studies will be needed to determine whether and how stem cell populations isolated from aged animals may be used.

"In the long-term, the translation between the MSC-based therapy in the porcine hibernating myocardium and regenerative medicine for humans with chronic coronary artery disease will lead to optimized MSC therapeuti cs that can be of clinical value in managing aging and curing disease," he said.

The research will be carried out in two phases. During the first phase, investigators will conduct extensive studies of the characteristics and potential of the targeted stem cells, including research on the influence of aging on the potency of MSCs (hibernating myocardium typically does not occur in young persons).

"If aging indeed impairs the function of these adult stem cells," said Lee, "genetic and tissue engineering might be used to boost the competency of aged MSCs."

He noted also that mesenchymal stem cells do not appear to generate a strong immune response. "If this characteristic is proven rigorously," he said, "and if we determine how these stem cells differentiate into cells for specific 'jobs,' it might provide the basis for 'off-the-shelf' use of these stem cells in future therapeutic applications."

The second phase of the project will involve injecting the stem cells into swine with hibernating myocardium. The researchers will track the cells' progress, evaluate their feasibility, and determine if cells engineering for enhanced survival, blood vessel regeneration and "homing potential" (the tendency to migrate properly to the heart rather than elsewhere) can better improve blood flow and tissue function in hibernating myocardium.


'"/>

Source:University at Buffalo


Related biology news :

1. New Finding May Aid Adult Stem Cell Collection
2. Adult stem cells aid recovery in animal model of cerebral palsy
3. Adult stem cells are touchy-feely, need environmental clues
4. Adults who go to bed lonely get stress hormone boost next morning
5. Columbia research lifts major hurdle to gene therapy for cancer
6. U of M researcher examines newly emerging deadly disease
7. NYU researchers simulate molecular biological clock
8. First atlas of key brain genes could speed research on cancer, neurological diseases
9. New research questions basic tenet of neuron function
10. Vital step in cellular migration described by UCSD medical researchers
11. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology: